• PMD4 SECONDARY CATARACT PROCEDURES DUE TO POSTERIOR CAPSULAR OPACIFICATION IN THE CZECH REPUBLIC: AN ANALYSIS OF HEALTH INSURANCE DATA

    Nov 1, 2019, 00:00

  • PCN79 A TARGETED LITERATURE REVIEW (TLR) OF THE EPIDEMIOLOGY AND ECONOMIC BURDEN OF ACUTE MYELOID LEUKEMIA (AML)

    Nov 1, 2019, 00:00

  • PSY4 THE USE OF EQ-5D VISUAL ANALOG SCALE (EQ-VAS) IN DISEASES AREAS WHERE EQ-5D IS INSENSITIVE TO CHANGES IN THE DISEASE STATUS: THE CASE OF LIPODYSTROPHY

    Nov 1, 2019, 00:00

  • PSU26 ANALYSIS THE PROGRESSION OF MARKET SHARE OF ONE-DAY SURGERY AMONG HUNGARIAN UNIVERSITIES

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PBI29 LITERATURE REVIEW ON TOTAL MEDICAL COSTS AND COST COMPONENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPIES

    Nov 1, 2019, 00:00

  • PND98 PATTERNS AND PREDICTION FOR COGNITIVE DECLINE IN ALZHEIMER'S PATIENTS AS ASSESSED BY THE MINI-MENTAL STATUS EXAM IN AN AMBULATORY ELECTRONIC MEDICAL RECORD

    Nov 1, 2019, 00:00

  • PCN102 DATA INTELLIGENCE FOR THE EVALUATION OF NEW TREATMENTS FOR BREAST CANCER: QUEST FOR A BETTER METHOD TO ESTIMATE AFFORDABILITY IN SCOTLAND

    Nov 1, 2019, 00:00

  • PND124 A REAL-WORLD DATA STUDY TO ANALYSE THE PHARMACOLOGICAL TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN SPAIN

    Nov 1, 2019, 00:00

  • PRS62 ASSESSMENT OF PRESCRIPTION PATTERN AND EVALUATION OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2019, 00:00

  • PRS40 CURRENT TREATMENT STATUS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IN JAPAN: A CLAIMS-BASED RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • Drugs Regulatory

    Nov 1, 2019, 00:00

  • PIN47 FACING LIMITED ALTERNATIVES TO TREAT MULTI-DRUG RESISTANT BACTERIA IN THE FIELD OF NOSOCOMIAL PNEUMONIA

    Nov 1, 2019, 00:00

  • PMD55 THE LEARNING CURVE AS A BARRIER IN THE CONDUCT OF RANDOMIZED CONTROLLED TRIALS WITH MEDICAL DEVICES - A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN478 HEALTH-RELATED QUALITY OF LIFE OF CANCER PATIENTS IN JAPAN: A POPULATION-BASED NATIONAL HEALTH AND WELLNESS SURVEY STUDY

    Nov 1, 2019, 00:00

  • CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

    Nov 1, 2019, 00:00

  • PMU92 THE DANISH MEDICINE COUNCIL'S PROCESS OF ASSESSING NEW HOSPITAL MEDICINES: AN ANALYSIS OF DECISIONS 2017-2019

    Nov 1, 2019, 00:00

  • PMH67 ANALYSIS OF PSYCHOTROPIC MEDICATIONS PRESCRIPTIONS IN TURKEY

    Nov 1, 2019, 00:00

  • PCN308 IDENTIFICATION OF VARIABLES THAT MAY INFLUENCE THE RECOMMENDATION INCLUDED IN THE THERAPEUTIC POSITIONING REPORT OF NEW ONCOLOGY PRODUCTS IN SPAIN

    Nov 1, 2019, 00:00

  • PNS415 PUBLISHING OBSERVATIONAL STUDIES VS RANDOMIZED CONTROLLED TRIALS - A PUBMED REVIEW

    Nov 1, 2019, 00:00

  • PMU15 ECONOMIC IMPACT OF PREVENAR 13 VACCINATION AGAINST PNEUMOCOCCAL PNEUMONIA HOSPITALIZATIONS IN DANES 65+ WITH A CHRONIC DISEASE - A MODELLED ANALYSIS

    Nov 1, 2019, 00:00

  • PRO36 BUDGET IMPACT ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR HEAMOPHILIA A PATIENTS WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDB47 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS) VS. HIPOS-ER (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - EMERGENCY ROOM) - A COMPARISON OF THE ECONOMIC OUTCOMES

    Nov 1, 2019, 00:00

  • PCN413 A BAYESIAN MIXTURE CURE MODEL USING INFORMATIVE PRIORS

    Nov 1, 2019, 00:00

  • Expanding Horizon of Outcome Studies in Oncology

    Nov 1, 2019, 00:00

  • MT4 COST ANALYSIS OF INTEGRATED VERSUS CONVENTIONAL OPERATING ROOMS

    Nov 1, 2019, 00:00

  • PDB63 COST-EFFECTIVENESS OF INSULIN PUMP AND CONTINUES GLUCOSE MONITORING VERSUS MULTIPLE DAILY INJECTIONS AND SELF-MONITORING OF BLOOD GLUCOSE IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS

    Nov 1, 2019, 00:00

  • PCN81 COST-EFFECTIVENESS OF DABRAFENIB AND TRAMETINIB COMPARED TO PEMBROLIZUMAB AS ADJUVANT TREATMENT OF STAGE III HIGH-RISK BRAF V600E MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION: A BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN472 PATIENT REPORTED HEALTH STATE UTILITIES IN CUTANEOUS T-CELL LYMPHOMA (CTCL) - AN ANALYSIS OF EQ-5D AND SKINDEX-29 DATA COLLECTED FROM THE ALCANZA TRIAL

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMU86 A REVIEW OF TOP COUNTRIES CONTRIBUTING TO POSTERS PRESENTED AT ISPOR EUROPE 2018

    Nov 1, 2019, 00:00

  • PMU83 PATIENT-FOCUSED OUTCOMES IN THE AMNOG-PROCESS - STATUS QUO AND QUO VADIS

    Nov 1, 2019, 00:00

  • PNS50 ECONOMIC IMPACT OF THE DEVELOPMENT OF OUTPATIENT SURGERY IN FRANCE

    Nov 1, 2019, 00:00

  • PRO67 UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • AD3 ORAL ANTICOAGULANT PRESCRIPTION TRENDS, PROFILE USE AND DETERMINANTS OF ADHERENCE IN PATIENTS WITH ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00

  • PCV20 MACHINE LEARNING BETTER PREDICTS RISK AFTER ACUTE CORONARY SYNDROMES, IDENTIFIES HIGH-COST INDIVIDUALS AND THOSE WITH ELEVATED BURDEN OF UNCONTROLLED RISK FACTORS

    Nov 1, 2019, 00:00

  • PNS295 BEST WORST SCALING: FOR GOOD OR FOR BAD BUT NOT FOR BOTH

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PRS46 TREATMENT OF SEVERE ASTHMA IN PORTUGAL: INSIGHTS FROM A PHYSICIANS' SURVEY

    Nov 1, 2019, 00:00

  • PRO68 A SYSTEMATIC LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

    Nov 1, 2019, 00:00

  • PSY34 TWO SIDES OF THE SAME COIN? A DUAL MULTIPLE CRITERIA DECISION ANALYSIS OF NOVEL TREATMENTS FOR RHEUMATOID ARTHRITIS FROM PHYSICIANS' AND PATIENTS' PERSPECTIVES IN GREECE

    Nov 1, 2019, 00:00

  • PNS168 REFERENCE PRICE GROUPS (RPG) DEFINED FROM 2008 TO 2018 IN GERMANY - A DETAILED OVERVIEW AND DISCUSSION

    Nov 1, 2019, 00:00

  • PCN151 COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR WOMEN WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER IN FRANCE

    Nov 1, 2019, 00:00

  • PND16 A SEMI-STANDARDIZED SYMPTOM MENU TO FACILITATE GOAL ATTAINMENT SCALING IN DEMENTIA DRUG TRIALS: COMPARISON WITH TRADITIONAL APPROACHES

    Nov 1, 2019, 00:00

  • PMU25 USING MULTIPLE CRITERIA DECISION ANALYSIS (MCDA) TO CREATE A PRIORITY LIST OF CHRONIC NON-COMMUNICABLE DISEASES (NCDS) TO GUIDE HEALTH RESEARCH SPENDING

    Nov 1, 2019, 00:00

  • PND5 OVERCOMING MARKET ACCESS AND COMMERCIALIZATION CHALLENGES IN GENE THERAPIES FOR RARE CNS DISEASES: GENE THERAPY CLINICAL TRIALS FOR RARE CNS DISEASES LANDSCAPE

    Nov 1, 2019, 00:00

  • PNS159 PHARMACOECONOMICS AND HEALTH OUTCOME STUDIES IN TURKEY: ISPOR DATABASE SEARCH

    Nov 1, 2019, 00:00

  • PDG46 DOES NEW WAY TO IMPROVE PATIENTS ACCESS TO EXPENSIVE INNOVATIVE DRUGS IN POLAND WORK?

    Nov 1, 2019, 00:00

  • PRS56 MACHINE LEARNING PREDICTION OF ASTHMA NON-SCHEDULED VISITS IN THE BRAZILIAN PRIVATE HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PSY43 HEALTH STATE UTILITIES ASSOCIATED WITH SICKLE CELL DISEASE AND ITS TREATMENT: LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PND54 COST-OF-ILLNESS TRAJECTORIES AMONG NEWLY DIAGNOSED MS PATIENTS TREATED WITH INTERFERONS, GLATIRAMER ACETATE, OR NATALIZUMAB: HEALTHCARE, SICKNESS ABSENCE, AND DISABILITY PENSION COSTS IN SWEDEN

    Nov 1, 2019, 00:00

  • PDB84 MANAGEMENT OF PREDIABETES FROM THE PERSPECTIVE OF SPANISH PHYSICIANS AND COMMUNITY PHARMACISTS. DETECTA2 STUDY

    Nov 1, 2019, 00:00

  • Drugs Generics - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PBI25 COST OF STANDARD HALF-LIFE VERSUS EXTENDED HALF-LIFE RECOMBINANT COAGULATION FACTOR VIII IN PATIENTS WITH HEMOPHILIA A IN SPAIN: RESULTS FROM A PROBABILISTIC MODEL

    Nov 1, 2019, 00:00

  • New Frontiers in Oncology Cost Studies

    Nov 1, 2019, 00:00

  • PNS320 ANALYSIS OF MINIMAL IMPORTANT CHANGE THROUGH ITEM RESPONSE THEORY METHODS

    Nov 1, 2019, 00:00

  • Infectious Diseases - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PNS98 A QUALITATIVE EXPLORATION OF KNOWLEDGE, ATTITUDE AND PRACTICES OF PHYSICIANS ABOUT PHARMACOVIGIILANCE ACTIVITIES IN TERTIARY CARE HOSPITALS OF LAHORE, PAKISTAN

    Nov 1, 2019, 00:00

  • TP2 TREATMENT PATTERNS IN SPINAL MUSCULAR ATROPHY: INTERVIEWS WITH HEALTHCARE PROFESSIONALS IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PNS391 REAL WORLD USE OF VEHICLES BY OLDER PATIENTS TAKING SOLID ORAL MEDICATIONS: A SURVEY IN THE ONLINE HEALTH NETWORK PATIENTSLIKEME.

    Nov 1, 2019, 00:00

  • PIN66 COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME-AVIBACTAM VERSUS COLISTIN-MEROPENEM IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT ENTEROBACTERIACEAE IN COLOMBIA

    Nov 1, 2019, 00:00

  • PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) A ...

    Nov 1, 2019, 00:00

  • PRO66 INCIDENCE AND PREVALENCE OF T-CELL LYMPHOMA IN THE EMA MEMBER STATES: METHODOLOGY FOR ESTIMATION IN RARE MALIGNANCIES OF CTCL AND PTCL

    Nov 1, 2019, 00:00

  • PMU129 PERFORMANCE OF A COMPREHENSION QUESTION IN DISCRETE-CHOICE EXPERIMENT SURVEYS (DCE)

    Nov 1, 2019, 00:00

  • PRS61 A COMPARISON OF EUROPEAN MEDICINES AGENCY (EMA) AND FOOD AND DRUG ADMINISTRATION (FDA) PATIENT-REPORTED OUTCOME (PRO) GUIDANCES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2019, 00:00

  • PMU109 HOW DO NICE EVIDENCE REVIEW GROUPS AND APPRAISAL COMMITTEES PERCEIVE FRACTIONAL POLYNOMIAL METHODOLOGY IN TECHNOLOGY APPRAISALS?

    Nov 1, 2019, 00:00

  • PCN246 BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2- NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK

    Nov 1, 2019, 00:00

  • PIN25 EXPLORATORY ANALYSIS OF THE ECONOMICALLY JUSTIFIABLE PRICE OF AN RSV VACCINE FOR THE ELDERLY IN THE NETHERLANDS AND THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • CV2 NATIONAL SAVINGS FROM TELEHEALTH CARE IN HEART FAILURE RESULTS FROM THE DANISH TELECARE NORTH TRIAL

    Nov 1, 2019, 00:00

  • PCV151 REAL WORLD EVIDENCE OF THE EFFECT OF PERIPHERAL ARTERIAL DISEASE (PAD) ON PATIENT HEALTH OUTCOMES AND COSTS IN AUSTRALIA.

    Nov 1, 2019, 00:00

  • PCN349 VALUE OF INFORMATION ANALYSIS GUIDING THE REIMBURSEMENT DECISION OF OLAPARIB FOR METASTATIC BREAST CANCER

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Medical Technologies

    Nov 1, 2019, 00:00

  • PDB67 MAIN PREDICTORS OF DIABETES MELLITUS TYPE 2 (DM2T) IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PIH47 COMPARISON OF CAESAREAN SECTION RATES IN GEOGRAPHICAL AREAS OF WHO EUROPEAN REGION

    Nov 1, 2019, 00:00

  • PSY11 ECONOMIC BURDEN OF PSORIASIS IN GREECE: RESULTS OF A MULTICENTRE, PROSPECTIVE, EPIDEMIOLOGICAL STUDY

    Nov 1, 2019, 00:00

  • PDB89 COST-EFFECTIVENES ANALYSIS OF USING PEGVISOMANT FOR TREATMENT OF ACROMEGALY IN RUSSIA

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PMH20 COST-EFFECTIVENESS OF INCREASING THE EFFICIENCY OF THE DETOXIFICATION PROCESS PRIOR TO INITIATION OF EXTENDED-RELEASE NALTREXONE FOR THE TREATMENT OF OPIOID USE DISORDER

    Nov 1, 2019, 00:00

  • Medical Devices - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PRO101 ORPHAN DRUG REIMBURSEMENT IN ENGLAND AND IMPLICATIONS FOR PATIENT ACCESS

    Nov 1, 2019, 00:00

  • PGI17 COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN

    Nov 1, 2019, 00:00

  • Surgery - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCN475 PERCEPTIONS AND EXPERIENCES OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER: A UK CASE STUDY

    Nov 1, 2019, 00:00

  • PCN57 A MULTI-STAKEHOLDER PERSPECTIVE ON THE CHALLENGES IN DEMONSTRATING THE LONG-TERM BENEFIT OF CANCER IMMUNOTHERAPY

    Nov 1, 2019, 00:00

  • PCV24 REAL-WORLD COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PND27 BUDGET IMPACT MODEL (BIM) FOR THE EQUISTASI® DEVICE

    Nov 1, 2019, 00:00

  • ON8 CHEMOTHERAPY INDUCED NAUSEA VOMITING: VALIDATION OF RISK SCORING ALGORITHM IN PATIENTS WITH GYNECOLOGICAL AND GASTROINTESTINAL CANCERS

    Nov 1, 2019, 00:00

  • PCN462 ACCURACY OF RISK SCORING SYSTEM TO DETERMINE DELAYED CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PNS205 SURROGATE VALIDATION IN GERMAN AMNOG BENEFIT ASSESSMENTS

    Nov 1, 2019, 00:00

  • PRO79 EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PDG80 INFLUENCING FACTORS FOR A RENEWED BENEFIT ASSESSMENT IN THE GERMAN HTA PROCESS - A COMPARATIVE OVERVIEW OF §13 AND §14 IN CHAPTER 5 OF THE G-BA RULES OF PROCEDURE

    Nov 1, 2019, 00:00

  • PMD52 MEDICAL DEVICES AND SUSTAINABILITY: CLAIMS AND EVIDENCE IN NICE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PMU24 ECONOMIC EVALUATION OF BIOCELLULOSE WOUND DRESSINGS FOR THE MANAGEMENT OF CHRONIC LEG ULCERS IN CANADA

    Nov 1, 2019, 00:00

  • Infectious Diseases - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS149 STATUS OF COMPASSIONATE USE PROGRAMMES (CUP) IN THE EU-5 (FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM)

    Nov 1, 2019, 00:00

  • PBI59 THE REIMBURSEMENT STATUS OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE

    Nov 1, 2019, 00:00

  • PND74 PREVALENCE OF PROGRESSIVE SUPRANUCLEAR PALSY (PSP) IN EUROPE, JAPAN AND THE USA

    Nov 1, 2019, 00:00

  • PNS314 RELAXING THE MEMORYLESS PROPERTY WITHIN A MARKOV MODEL

    Nov 1, 2019, 00:00

  • PCN59 CHARACTERISING ERRORS INCURRED BY MODEL SELECTION BASED ON AIC FOR EXTRAPOLATION OF SURVIVAL IN HEALTH TECHNOLOGY ASSESSMENT - A SIMULATION STUDY

    Nov 1, 2019, 00:00

  • PNS407 PATIENT SELECTION PROCESS IN REAL-WORLD DATA FROM ELECTRONIC HEALTH RECORDS - SUGGESTED STANDARDISED PROCESS FOR SELECTING PATIENTS

    Nov 1, 2019, 00:00

  • PMS42 PREVALENCE, PAIN INTENSITY AND DISABILITY OF LOW BACK PAIN AMONG INDIAN POPULATION. A CROSS SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PIN117 THE COST OF INFLUENZA RELATED HOSPITALIZATIONS IN ELDERLY IN TURKEY

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PSY29 EARLY-STAGE MYCOSIS FUNGOIDES: INCIDENCE AND DIFFERENTIAL SURVIVAL

    Nov 1, 2019, 00:00

  • PCV49 COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS

    Nov 1, 2019, 00:00

  • PMU122 UPDATING DISABILITY WEIGHTS FOR MEASUREMENT OF HEALTHY LIFE EXPECTANCY AND DISABILITY-ADJUSTED LIFE YEAR IN KOREA

    Nov 1, 2019, 00:00

  • PCN427 ASSESSING THE PERFORMANCE OF PARAMETRIC SURVIVAL MODELS USING REAL WORLD EVIDENCE IN CML, LUNG AND PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PCV5 3C-HF PROGNOSTIC SCORE TO PREDICT WORSENING CARDIAC FUNCTION AMONG CONGESTIVE HEART FAILURE PATIENTS IN UNITED STATES AND EUROPE

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCN379 HTA ASSESSMENTS OF METASTATIC UROTHELIAL CARCINOMA TREATMENT IN EU COUNTRIES

    Nov 1, 2019, 00:00

  • PCN105 COST-UTILITY OF NIVOLUMAB FOR RECURRENT OR METASTATIC HEAD AND NECK CANCER (R/M SCCHN) IN FRANCE

    Nov 1, 2019, 00:00

  • PMS3 A COMPARATIVE ANALYSIS OF THE QUALITY OF LIFE OF PATIENTS TREATED WITH MINIMAL INVASIVE ANTERIOR HIP REPLACEMENT SURGERY AND NON-SURGICAL PATIENTS

    Nov 1, 2019, 00:00

  • PNS67 WELLBEING VALUATION METHOD ON DETERMINING MONETARY VALUE OF WELFARE LOSS DUE TO HEALTHCARE ACCESS BARRIERS

    Nov 1, 2019, 00:00

  • PCV127 PATIENT PREFERENCES REGARDING ORAL ANTICOAGULANTS: RESULTS OF A DISCRETE CHOICE EXPERIMENT IN SPANISH PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN-K ANTAGONISTS

    Nov 1, 2019, 00:00

  • AI3 DEVELOPMENT OF A DECISION-AID FOR PATIENTS WITH DEPRESSION CONSIDERING TREATMENT OPTIONS: PREDICTION OF TREATMENT RESPONSE USING A DATA-DRIVEN APPROACH

    Nov 1, 2019, 00:00

  • PCV142 ESTIMATING THE IMPACT ON RECURRENT HOSPITAL ADMISSIONS AND AMBULATORY VISITS OF PRESCRIBING FERRIC CARBOXYMALTOSE IN IRON DEFICIENCY PATIENTS WITH CHRONIC HEART FAILURE: A RETROSPECTIVE RWE STUDY USING A HOSPITAL REGISTRY IN SPAIN

    Nov 1, 2019, 00:00

  • PBI69 INSIGHTS INTO FUTURE AUTOIMMUNE PRICING DYNAMICS IN EU5 THE US, USING LEARNINGS FROM RHEUMATOID ARTHRITIS

    Nov 1, 2019, 00:00

  • CL3 THE ASSOCIATION BETWEEN TREATMENT INTENSITY AND ADHERENCE TO LIPID-LOWERING THERAPIES AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN PRIMARY AND SECONDARY CARE: A SWEDISH REGISTRY-BASED STUDY

    Nov 1, 2019, 00:00

  • PND21 PROJECT HERCULES: A NEW PARADIGM FOR PATIENT-CENTRED COLLABORATION IN HTA

    Nov 1, 2019, 00:00

  • PSY20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PSU42 PHARMACOVIGILANCE OF ANESTHETICS IN THE DEPARTMENT OF GENERAL SURGERY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PCN534 BARRIERS AND FACILITATORS TO IMPLEMENTING ELECTRONIC PATIENT-REPORTED OUTCOMES (PROS) IN CANCER CLINICAL TRIALS: INTERVIEW RESULTS FROM CLINICAL RESEARCH STAFF AND PATIENTS

    Nov 1, 2019, 00:00

  • PND132 CLAIMS DATABASE ANALYSIS OF HEADACHE AND MIGRAINE IN SPAIN 2011-2016: PATIENT PROFILE, HEALTHCARE MANAGEMENT AND DIRECT MEDICAL COSTS

    Nov 1, 2019, 00:00

  • PCN157 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN

    Nov 1, 2019, 00:00

  • AD2 DYNAMICS OF SWITCHING, ADHERENCE, AND PERSISTENCE OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS USE: AN AUSTRALIAN PERSPECTIVE

    Nov 1, 2019, 00:00

  • Infectious Diseases - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PMD6 COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A DUTCH HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS333 EXTRAPOLATING SURVIVAL BY ASSUMING PROPORTIONAL HAZARDS BETWEEN GENERAL POPULATION MORTALITY AND DISEASE SPECIFIC MORTALITY

    Nov 1, 2019, 00:00

  • PNS71 ROLE OF INFORMATION IN DEMAND FOR HEALTH SERVICES: AN INSTRUMENTAL VARIABLE APPROACH

    Nov 1, 2019, 00:00

  • PRO139 A PATIENT-CENTRIC APPROACH TO COST OF ILLNESS RESEARCH: A CASE EXAMPLE OF PATIENT ENGAGEMENT TO IDENTIFY THE HIDDEN COSTS ASSOCIATED WITH BLINDNESS DUE TO INHERITED RETINAL DYSTROPHIES

    Nov 1, 2019, 00:00

  • PCN66 A COST-UTILITY ANALYSIS OF NIVOLUMAB IN THE ADJUVANT TREATMENT OF MELANOMA IN FRANCE

    Nov 1, 2019, 00:00

  • PDB19 THE BIAS OF IGNORING CARDIOPROTECTIVE EFFECTS IN COST-EFFECTIVENESS ANALYSIS IN DIABETES

    Nov 1, 2019, 00:00

  • PCN511 ASSOCIATED FACTORS AFFECTING RECURRENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM IN KOREA

    Nov 1, 2019, 00:00

  • PNS77 CHALLENGES OF STUDIES ON ECONOMIC EVALUATION IN CHILD HEALTH IN CHINA-BASED ON A REVIEW OF PUBLISHED LITERATURE

    Nov 1, 2019, 00:00

  • CP4 META-ANALYSIS POWERED BY ARTIFICIAL INTELLIGENCE

    Nov 1, 2019, 00:00

  • Multiple Diseases - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PRS28 ECONOMIC AND ENVIRONMENTAL IMPACTS OF A VOLUNTARY SHIFT IN INHALER PRESCRIBING IN THE ENGLISH NHS

    Nov 1, 2019, 00:00

  • PNS59 INCORPORATING THE PATIENT'S PERSPECTIVE IN ECONOMIC EVALUATIONS OF HEALTHCARE

    Nov 1, 2019, 00:00

  • PNS373 IDENTIFICATION AND RECOMMENDATIONS OF READABILITY TESTS FOR THE EVALUATION OF CLINICAL OUTCOME ASSESSMENTS

    Nov 1, 2019, 00:00

  • PIN52 STUDIES REPORTING COSTS ASSOCIATED WITH INVASIVE MENINGOCOCCAL DISEASE IN EU-27: METHODOLOGY AND OUTCOMES

    Nov 1, 2019, 00:00

  • PCV76 COMTEMPORARY HEART FAILURE TREATMENT PATTERN AND COST IN CHINESE PATIENTS POPULATIONS

    Nov 1, 2019, 00:00

  • Effect of Reflection and Deliberation on Health State Values: A Mixed-Methods Study

    Nov 1, 2019, 00:00

  • PRS9 HOW CLINICAL TRIALS INCORPORATED OUTCOMES RELEVANT FOR HEALTH ECONOMIC EVALUATION: AN EVIDENCE GAP ANALYSIS BASED ON SYSTEMATIC REVIEW OF CLINICAL TRIALS FOR MODERATE-TO-SEVERE ASTHMA IN JAPAN

    Nov 1, 2019, 00:00

  • PNS237 CLINICAL OUTCOME ASSESSMENTS AS A CONDITION IN HTA RECOMMENDATIONS: THE CANADIAN PERSPECTIVE

    Nov 1, 2019, 00:00

  • PRO104 DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Nov 1, 2019, 00:00

  • PMU10 CONSIDERATIONS FOR THE TRANSLATION AND LINGUISTIC VALIDATION OF CLINICAL OUTCOME ASSESSMENTS (COAS) IN VARIANTS OF SPANISH FOR THE UNITED STATES

    Nov 1, 2019, 00:00

  • PMD48 OPPORTUNITIES AND CHALLENGES FOR NOVEL MEDICAL DEVICES LAUNCHING IN EUROPE IN THE HOSPITAL SETTING

    Nov 1, 2019, 00:00

  • PND86 COST-UTILITY ANALYSIS OF DELTA-9-TETRAHIDROCANNABINOL AND CANNABIDIOL OROMUCOSAL SPRAY

    Nov 1, 2019, 00:00

  • PCN198 FRACTIONAL POLYNOMIAL MODELS FOR NETWORK META-ANALYSIS OF SURVIVAL DATA IN ECONOMIC EVALUATIONS: A CASE-STUDY ON THE COST-EFFECTIVENESS OF FULVESTRANT IN PREVIOUSLY-TREATED POSTMENOPAUSAL, OESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST ...

    Nov 1, 2019, 00:00

  • PND59 BUDGET IMPACT ANALYSIS OF THE NATIONAL CLINICAL GUIDELINE FOR APPROPRIATE PRESCRIBING OF PSYCHOTROPIC MEDICATION IN PEOPLE WITH DEMENTIA

    Nov 1, 2019, 00:00

  • PIN10 GROWTH FACTORS AND THEIR IMPACT ON HEALTHCARE UTILIZATION AND COST IN CACHECTIC HIV PATIENTS

    Nov 1, 2019, 00:00

  • PRO111 REIMBURSEMENT OF ULTRA-ORPHAN MEDICINES: A NEW BEST-PRACTICE FRAMEWORK?

    Nov 1, 2019, 00:00

  • Patient Reported Outcomes Quality of Life Studies

    Nov 1, 2019, 00:00

  • PNS387 MULTI-CRITERIA DECISIONAL ANALYSIS ON NON-EMERGENCY MEDICAL TRANSPORT IN HONG KONG CONTEXT

    Nov 1, 2019, 00:00

  • PRO108 ANALYSIS OF NICE AND US ICER HTA OUTCOMES FOR ULTRA-ORPHAN MEDICINAL PRODUCTS

    Nov 1, 2019, 00:00

  • PNS305 PATIENT-LEVEL SIMULATION MODELS: THE POWER OF PARALLEL WORLDS

    Nov 1, 2019, 00:00

  • PNS184 THE VALUE OF BLOOD IN SUB-SAHARAN AFRICA

    Nov 1, 2019, 00:00

  • PND10 ANTI-TNF-α INHIBITORS IN PREVENTING ALZHEIMER'S DISEASE (AD): A RETROSPECTIVE REVIEW USING BOTH EMR AND CLAIMS DATA

    Nov 1, 2019, 00:00

  • PNS219 TARGETED LITERATURE REVIEW AND PAYERS' PERSPECTIVES ON THE CURRENT PROGRESS OF HTA SYSTEM IMPLEMENTATION IN THE MENA REGION

    Nov 1, 2019, 00:00

  • PRO18 BUDGET IMPACT ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE

    Nov 1, 2019, 00:00

  • PCN216 THE SOCIETAL IMPACT OF LENALIDOMIDE IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA IN GERMANY

    Nov 1, 2019, 00:00

  • CV3 MECHANICALLY EXPANDED VERSUS SELF-EXPANDING TRANSCATHETER AORTIC VALVE REPLACEMENT IN HIGH-RISK PATIENTS WITH AORTIC STENOSIS: A BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PCV110 COST-EFFECTIVENESS OF SUTURELESS AORTIC VALVE REPLACEMENT VERSUS CONVENTIONAL AORTIC VALVE REPLACEMENT AND TRANSCATHETER AORTIC VALVE IMPLANTATION IN BRAZIL

    Nov 1, 2019, 00:00

  • PNS46 POISSON REPRESENTATION OF MARKOV COHORT STATE-TRANSITION MODELS

    Nov 1, 2019, 00:00

  • PCN231 COST-EFFECTIVENESS OF REGORAFENIB FOR METASTATIC COLORECTAL CANCER IN THE CONTEXT OF THE HEALTHCARE SYSTEM OF KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PNS211 SWOT ANALYSIS FOR CREATION OF HTA ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • SP4 EXPLORING HETEROGENEITY IN PREFERENCES FOR ATTRIBUTES OF PHARMACEUTICAL TREATMENTS FOR OSTEOARTHRITIS AND CHRONIC LOW BACK PAIN IN THE UNITED KINGDOM: A LATENT CLASS APPROACH

    Nov 1, 2019, 00:00

  • PMU98 UTILITY OF EARLY ACCESS TO MEDICINES SCHEME DATA FOR NICE DECISION-MAKING

    Nov 1, 2019, 00:00

  • PRO32 DE NOVO ECONOMIC MODEL TO ASSESS THE IMPACT OF SIZE AND DURABILITY OF EFFECT OF CURATIVE CELL AND GENE THERAPIES IN TREATMENT OF PATIENTS WITH CONGENITAL DYSERYTHROPOIETIC ANEMIA (CDA)

    Nov 1, 2019, 00:00

  • PCN171 COST AND HEALTHCARE RESOURCE UTILIZATION (HRU) RESULTING FROM IMMUNE-RELATED ADVERSE EVENTS (IRAES) AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICIS)

    Nov 1, 2019, 00:00

  • PNS208 VALUE AND HEALTH TECHNOLOGY ASSESSMENT: TRANSPARENCY IN USE OF PEER-REVIEWED PUBLICATIONS

    Nov 1, 2019, 00:00

  • PRO80 COMPARISON OF EARLY ACCESS PROGRAMMES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS354 MARKET ACCESS AS DEFINED BY MARKET ACCESS (MA), HEALTH ECONOMICS, AND OUTCOMES RESEARCH (HEOR) PROFESSIONALS

    Nov 1, 2019, 00:00

  • PIN33 COST-EFFECTIVENESS OF CURRENT PNEUMOCOCCAL VACCINES IN OLDER ADULTS IN EUROPEAN SETTINGS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN8 EXAMINATION OF FACTORS INFLUENCING THE OCCURRENCE OF THROMBOSIS IN MYELOPROLIFERATIVE NEOPLASMS (MPN) BASED ON HUNGARIAN NATIONAL REGISTRY DATA

    Nov 1, 2019, 00:00

  • PNS404 USING DATA WAREHOUSES TO OPTIMIZE HEALTHCARE DECISION MAKING

    Nov 1, 2019, 00:00

  • PMU147 PUBLICATION PATTERNS OF HEALTH ECONOMIC OUTCOME DATA OVER 2 DECADES: AN INCREASE IN PEER-REVIEWED HEOR PUBLICATIONS ACROSS INFLAMMATORY DISEASES

    Nov 1, 2019, 00:00

  • PND29 THE COST OF ACHIEVING NEDA WHILE USING TWO ALTERNATIVE FORMULATIONS OF INTERFERON BETA-1A FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN PORTUGAL: LET'S LOOK AT EVIDENCE

    Nov 1, 2019, 00:00

  • PMU88 WHAT IS THE ROLE OF THE COMPANY EVIDENCE SUBMISSION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) MULTIPLE TECHNOLOGY APPRAISALS?

    Nov 1, 2019, 00:00

  • PNS123 IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE IN INDONESIA

    Nov 1, 2019, 00:00

  • PCN167 SELF-REPORTED OUT-OF-POCKET EXPENSES, INCOME LOSS, AND INFORMAL CARE INCURRED BY CANCER PATIENTS IN SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PMU14 NON-MEDICAL SWITCHING AT THE HOSPITAL: A SYSTEMATIC REVIEW ON THERAPEUTIC CLASSES AND PATHOLOGIES THAT ARE APPROPRIATE TO ACHIEVE SAVINGS

    Nov 1, 2019, 00:00

  • PDG15 EFFICIENCY AND PRODUCTION OF THE AREA OF PREPARATION OF INTRAVENOUS ADMIXTURES AND STERILE MEDICATIONS

    Nov 1, 2019, 00:00

  • PSY13 BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PCV10 EFFECT OF LOW PRIME VOLUME ON HEMATOCRIT IN CORONARY ARTERY BYPASS SURGERY

    Nov 1, 2019, 00:00

  • PBI18 ESTIMATION OF THE HEALTHCARE RESOURCE UTILIZATION (HCRU) COSTS IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA RECEIVING TISAGENLECLEUCEL: A MICRO-COSTING STUDY IN THE UK AND FRANCE

    Nov 1, 2019, 00:00

  • PDB117 PATIENT TREATMENT SATISFACTION AND STUDY STAFF PERCEPTIONS OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PDB127 BUDGET-IMPACT ANALYSIS (BIA) OF OBESITY FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2019, 00:00

  • PNS228 TIME FOR REIMBURSEMENT AND PRICING FOR DRUGS DEPENDING ON THE EARLY ACCESS STATUS IN FRANCE (WITH OR WITHOUT ATU)

    Nov 1, 2019, 00:00

  • HT3 WHAT INFLUENCES THE PROBABILITY TO BE SUCCESSFUL IN AN ONCOLOGY HTA? AN ANALYSIS OF ONCOLOGY HTA DECISIONS IN GERMANY, SPAIN AND THE UK

    Nov 1, 2019, 00:00

  • PNS251 FACTORS ASSOCIATED WITH THE OUTCOMES OF RAPID REVIEWS SUBMITTED TO THE NCPE

    Nov 1, 2019, 00:00

  • PCN440 NETWORK META-ANALYSIS USING FRACTIONAL POLYNOMIALS: HEURISTIC FOR MODEL SELECTION INCORPORATING BEYOND-TRIAL EXTRAPOLATIONS (A MELANOMA EXAMPLE)

    Nov 1, 2019, 00:00

  • PRO27 IMPLICATIONS OF INDICATION EXPANSION OF ORPHAN DESIGNATED DRUGS ON EXISTING PRICES ACROSS EUROPEAN MARKETS

    Nov 1, 2019, 00:00

  • PNS304 IN SEARCH OF A PAN-EUROPEAN VALUE SET; APPLICATION FOR EQ-5D-3L: THE PECUNIA PROJECT

    Nov 1, 2019, 00:00

  • PNS405 DERIVING DATA FOR COST-EFFECTIVENESS MODELS FROM THE FRENCH SNDS DATABASE: A FEASIBILITY ASSESSMENT

    Nov 1, 2019, 00:00

  • PCN132 SYSTEMATIC REVIEW OF ECONOMIC BURDEN IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS

    Nov 1, 2019, 00:00

  • Neurological Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PDG106 EFFECTS OF STATIN THERAPY ON LONG-TERM HEALTH CARE OUTCOMES AND MEDICAL COST-BASED ON CHINA REGIONAL HEALTH INSURANCE CLAIM DATABASE

    Nov 1, 2019, 00:00

  • PCN31 TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HCRU) IN SECOND-LINE (2L) ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN ASIAN VERSUS WESTERN COUNTRIES

    Nov 1, 2019, 00:00

  • PCN354 RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON PROSTATE CANCER: RESULTS, RATIONALE, AND TRENDS

    Nov 1, 2019, 00:00

  • PAM6 BUDGET IMPACT ANALYSIS OF THE ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL IN OBESE PATIENTS IN ITALY

    Nov 1, 2019, 00:00

  • PCN317 VALIDATION OF A STANDARD SET OF PATIENT-CENTERED OUTCOMES FOR LUNG CANCER IN SPAIN

    Nov 1, 2019, 00:00

  • PUK17 EARLY CONVERSION FROM INTRAVENOUS TO ORAL ANTIBIOTICS: ASSESSMENT AND EVALUATION OF ECONOMIC OUTCOMES IN HOSPITALIZED PATIENTS

    Nov 1, 2019, 00:00

  • PRS70 APPLYING DIFFERENT MEASURES TO ASSESS PATIENTS' NON-ADHERENCE: RESULTS OF A LINKED DATA STUDY OF PATIENTS WITH ASTHMA IN GERMANY

    Nov 1, 2019, 00:00

  • PNS185 RELATIONSHIP BETWEEN PARTIAL VALUES AND SCORING SCALE FOR EACH CRITERION OF THE EVIDEM 10TH EDITION CORE MODEL IN JAPAN

    Nov 1, 2019, 00:00

  • PNS25 EVALUATION OF THE SCIENTIFIC ACTIVITY OF MEDICAL UNIVERSITIES AND RESEARCH CENTERS TO CREATE THE NATIONAL STRATEGY OF THE MEDICAL SCIENCE DEVELOPMENT

    Nov 1, 2019, 00:00

  • PRO138 PRODUCTIVITY LOSSES IN PEOPLE WITH CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD EVIDENCE STUDY

    Nov 1, 2019, 00:00

  • PIN112 DISPARITIES AND SIMILARITIES IN THE INFLUENZA VACCINATION RECOMMENDATIONS ACROSS UNITED STATES AND EUROPE

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS259 NATIONAL HTA IMPLEMENTATION IN MIDDLE-INCOME COUNTRIES, THE CASE OF JORDAN

    Nov 1, 2019, 00:00

  • PRO51 COST-EFFECTIVENESS AND BUDGET IMPACT OF ONASEMNOGENE ABEPARVOVEC FOR SPINAL MUSCULAR ATROPHY TYPE 1: POST-HOC ANALYSIS OF A MODEL DEVELOPED BY ICER

    Nov 1, 2019, 00:00

  • PRO151 PROJECT HERCULES: A MODIFIED DELPHI SURVEY TO INFORM A BURDEN-OF-ILLNESS STUDY IN DUCHENNE MUSCULAR DYSTROPHY

    Nov 1, 2019, 00:00

  • PCN106 A REVIEW OF DECISION ANALYTIC MODELS TO EVALUATE THE COST-EFFECTIVENESS OF CANCER TREATMENTS: 5-YEARS OF PUBLICATIONS AND SINGLE-TECHNOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PNS179 HOW DOES EXTERNAL REFERENCE PRICING FOR MEDICARE PART B DRUGS COMPARE TO OTHER COST METRICS AVAILABLE IN THE UNITED STATES?

    Nov 1, 2019, 00:00

  • PMH61 NEUROLEPTIC THERAPY COMPLIANCE DIFFERS AMONG PATIENTS TREATED BY DIFFERENT PSYCHIATRISTS

    Nov 1, 2019, 00:00

  • PND42 THE PRODUCTIVITY IMPACT OF EXCEEDING THE LEGAL TIME FOR PRICING AND REIMBURSEMENT DECISION OF ERENUMAB IN THE TREATMENT OF MIGRAINE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PNS198 PHARMACY COST OF PREVENTING ADVERSE DRUG EVENTS BY PHARMACISTS' INTERVENTIONS ON PRESCRIBING ERRORS

    Nov 1, 2019, 00:00

  • PCV101 REAL-WORLD COST AND EFFECTIVENESS ANALYSIS OF POST-ACUTE CARE VS. NON-PAC FOR STROKE PATIENTS AFTER DISCHARGE FROM HOSPITAL

    Nov 1, 2019, 00:00

  • PCN385 PAY-FOR-PERFORMANCE IN ONCOLOGY: A SUCCESSFUL STORY FROM BULGARIA

    Nov 1, 2019, 00:00

  • PCN513 RETROSPECTIVE STUDY DESCRIBING THE DEMOGRAPHIC CHARACTERISTICS, INCIDENCE, TREATMENT, COMORBIDITIES, MORTALITY, AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH MYELOFIBROSIS AND POLYCYTHEMIA VERA IN SWEDEN

    Nov 1, 2019, 00:00

  • PSS15 REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PBI55 FUTURE TRENDS ON THE BIOSIMILAR UPTAKE IN THE EU5 AND THE US

    Nov 1, 2019, 00:00

  • PMS7 EFFICACY EXAMINATION OF PILATES TRAINING AMONG HEALTHY WOMEN ON THE CHANGE OF TRUNK STATE, POSTURE, LUMBAR MOTOR CONTROL ABILITY AND BALANCE

    Nov 1, 2019, 00:00

  • PCN53 CHECKPOINT INHIBITOR USE AND THE OCCURRENCE OF INSULIN-DEPENDENT OR DRUG-INDUCED DIABETES: WHAT CAN WE LEARN FROM REAL WORLD DATA?

    Nov 1, 2019, 00:00

  • PCN339 INCORPORATING COMPANION DIAGNOSTICS (CDX) IN COST-EFFECTIVENESS MODELS (CEMS) SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE). A REVIEW

    Nov 1, 2019, 00:00

  • PDB107 A COMPARISON BETWEEN THE EQ-5D-5L AND THE SF-6D IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Nov 1, 2019, 00:00

  • PCN256 RESULTS FROM THE CALIBRATION OF A MICROSIMULATION COLON CANCER SCREENING FRENCH MODEL

    Nov 1, 2019, 00:00

  • PNS256 PUBLIC VIEWS ON PRIORITY-SETTING CRITERIA FOR LIMITED HEALTHCARE RESOURCE

    Nov 1, 2019, 00:00

  • PBI50 LEVERAGING OUTCOME BASED AND PORTFOLIO AGREEMENTS TO GUARANTEE CLINICAL OUTCOMES: INNOVATIVE PAYMENT MODELS FOR HIGH COST ONE-TIME TREATMENTS

    Nov 1, 2019, 00:00

  • PCN86 HEALTHCARE RESOURCE UTILIZATION FOR CETUXIMAB + CHEMOTHERAPY ADMINISTERED EVERY OTHER WEEK VS ONCE WEEKLY FOR TREATMENT OF METASTATIC COLORECTAL CANCER: REAL-WORLD OUTCOMES FROM A US CLAIMS DATABASE STUDY

    Nov 1, 2019, 00:00

  • PNS261 THE HEALTH ECONOMIC DOMAIN WITHIN HEALTH TECHNOLOGY ASSESSMENTS IN GERMANY — FIRST RESULTS AND ENSUING CONSEQUENCES OF THEMENCHECK MEDIZIN

    Nov 1, 2019, 00:00

  • PNS175 THE IMPACT OF RE-PRICING POLICY ON THE PRICE OF ANTI-CANCER DRUGS FROM 2007 TO 2017 IN SOUTH KOREA: A RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PMH28 ASSESSING THE LIFE-CYCLE VALUE ADDED OF SECOND-GENERATION ANTIPSYCHOTICS IN SWEDEN AND THE UK: THE CASE OF RISPERIDONE

    Nov 1, 2019, 00:00

  • PNS279 ASSESSING THE LIKELIHOOD OF RECEIVING A POSITIVE RECOMMENDATION THROUGH NICE'S STA PROCESS IN LINE WITH THE INDICATED PATIENT POPULATION

    Nov 1, 2019, 00:00

  • PCV137 ADHERENCE TO ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS OF A MULTI-COUNTRY STUDY

    Nov 1, 2019, 00:00

  • PCV139 EUROPEAN SURVEY ON STABLE ANGINA: REAL WORLD INSIGHTS ON PATIENTS’ CHARACTERISTICS, PERCEPTION OF DISEASE, AND QUALITY OF LIFE

    Nov 1, 2019, 00:00

  • PCN326 ASSESSMENT OF THE ONCOLOGICAL OFFER AMONG ITALIAN REGIONS: A PATIENT-CENTERED ANALYSIS

    Nov 1, 2019, 00:00

  • PIN109 DETERMINING THE BURDEN OF CARBAPENEM-RESISTANT GRAM-NEGATIVE INFECTIONS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Nov 1, 2019, 00:00

  • PCV28 CHARACTERIZATION OF COSTS AND PATIENTS WITH INCIDENT HEART FAILURE (HF) INCURRING THE HIGHEST HEALTHCARE COSTS FROM SECONDARY CARE: A RETROSPECTIVE, POPULATION-BASED COHORT STUDY IN SWEDEN

    Nov 1, 2019, 00:00

  • PCN181 ACCELERATING EARLY COST-EFFECTIVENESS MODELING IN ONCOLOGY USING AN INDICATION-AGNOSTIC WEB-BASED PLATFORM: A RETROSPECTIVE CASE STUDY OF NIVOLUMAB PRE-TREATED METASTATIC SMALL-CELL LUNG CANCER POPULATION

    Nov 1, 2019, 00:00

  • PRO72 MARKET ACCESS, PRICING AND REIMBURSEMENT PROCESSES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT

    Nov 1, 2019, 00:00

  • PNS100 A STUDY OF KNOWLEDGE, ATTITUDE AND PRACTICE REGARDING ADMINISTRATION OF PAEDIATRIC DOSAGE FORMS

    Nov 1, 2019, 00:00

  • PMU124 ATTENDING PHYSICIAN MODELS OF CARE AND PATIENT OUTCOMES

    Nov 1, 2019, 00:00

  • PBI22 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A SPANISH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PND57 INFORMAL CARE COST IN NEUROLOGIC DISORDERS WITH THE CONTINGENT VALUATION METHOD

    Nov 1, 2019, 00:00

  • Toward a Smaller Design for EQ-5D-5L Valuation Studies

    Nov 1, 2019, 00:00

  • PNS160 ESTIMATING THE MARKET VALUE OF PERSONAL HEALTH RECORDS: THE CASE OF INDIVIDUAL DATA OWNERSHIP

    Nov 1, 2019, 00:00

  • PMD25 COMPARING ECONOMIC IMPACT OF CENTRIFUGAL AND MEMBRANE THERAPEUTIC PLASMA EXCHANGE IN A SINGLE INSTITUTION IN THAILAND

    Nov 1, 2019, 00:00

  • PIN40 COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS IN RUSSIA

    Nov 1, 2019, 00:00

  • PCN517 VARIABILITY OF COST TRAJECTORIES OVER THE LAST YEAR OF LIFE; AN EXPLORATIVE STUDY IN PATIENTS WITH ADVANCED BREAST CANCER IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCV85 THE LONG-TERM EFFECT OF PARTICULATE MATTER(PM2.5, PM10) ON INCIDENCE AND MORTALITY OF MYOCARDIAL INFARCTION(MI): A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN369 WHAT IS THE REGULATORY AND HTA LANDSCAPE OF NON-SMALL CELL LUNG CANCER DRUGS ACROSS THE EU5 COUNTRIES?

    Nov 1, 2019, 00:00

  • PRO34 COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE.

    Nov 1, 2019, 00:00

  • PCV107 HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASUREMENT IN PATIENTS WITH HYPERTENSION IN HONG KONG (HK) SAR,CHINA

    Nov 1, 2019, 00:00

  • PCV69 COST EFFECTIVENESS ANALYSIS OF TICAGRELOR VERSUS CLOPIDOGREL IN STEMI PATIENTS FROM NATIONAL HEART INSTITUTE PERSPECTIVE IN EGYPT

    Nov 1, 2019, 00:00

  • ON2 VARIATION IN METHODOLOGICAL APPROACH TO PRODUCTIVITY COST VALUATION: DISTRIBUTIONAL EFFECTS IN THE CASE OF PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PDG59 THE IMPACT OF TEMPORARY AUTHORIZATION USE (ATU) DOSSIER IN FRANCE SINCE THE CREATION OF FFIP (PHARMACEUTICAL INNOVATION FINANCING FUND) IN 2017

    Nov 1, 2019, 00:00

  • Drugs Generics - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCN42 CABOZANTINIB VERSUS STANDARD-OF-CARE COMPARATORS: A NETWORK META-ANALYSIS OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PDG35 RACE, SLEEP TESTING, AND TREATMENT DIFFERENCES BETWEEN NARCOLEPTIC PEDIATRIC POPULATIONS WITH AND WITHOUT CATAPLEXY: A FEDERATED ELECTRONIC MEDICAL RECORD (EMR) NETWORK ANALYSIS

    Nov 1, 2019, 00:00

  • PMU67 PERFORMACE-BASED SCHEMES IN ITALY: IMPACT OF THEIR APPLICATION IN THE LAST 5 YEARS (2013-2017)

    Nov 1, 2019, 00:00

  • PDG8 SYNCHRONISING MARKET AND BRAND SHAPING ACTIVITIES: THE IMPORTANCE OF POLICY AND BRAND ALIGNMENT

    Nov 1, 2019, 00:00

  • PRO119 A NOVEL MAPPING APPROACH FOR ESTIMATING UTILITIES IN NON-DYSTROPHIC MYOTONIA

    Nov 1, 2019, 00:00

  • PDB28 A HEALTH ECONOMIC AND DECISION MODELLING ANALYSIS PLAN FOR AN INTEGRATED DATABASE OF OVER 100 CLINICAL TRIALS MEASURING HYPOGLYCAEMIC ATTACKS FOR PEOPLE WITH DIABETES: A HEDMAP FOR HYPORESOLVE

    Nov 1, 2019, 00:00

  • PNS128 READY FOR PRIME TIME? HAVE EMA PRIME DESIGNATIONS SUPPORTED ACCELERATED REGULATORY APPROVAL AND PATIENT ACCESS?

    Nov 1, 2019, 00:00

  • PCV13 INCIDENCE AND COST OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ACENOCOUMAROL, IN GREECE

    Nov 1, 2019, 00:00

  • PNS260 INCLUSION OF NEW STRATEGIES IN THE UK'S CANCER DRUG FUND: WHAT WAS DECIDED IN FRANCE?

    Nov 1, 2019, 00:00

  • CE2 EFFICACY OF BRODALUMAB AND GUSELKUMAB IN PATIENTS WITH PLAQUE PSORIASIS WHO ARE INADEQUATE RESPONDERS TO USTEKINUMAB: A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC)

    Nov 1, 2019, 00:00

  • PMS75 BURDEN OF DISEASE AND UNMET NEEDS OF KNEE OSTEOARTHRITIS IN COLOMBIA

    Nov 1, 2019, 00:00

  • PCN294 THE IMPACT OF VALUE-BASED CARE ON ONCOLOGY SPECIALTY PHYSICIANS

    Nov 1, 2019, 00:00

  • PCN54 EFFICACY AND SAFETY OF MOGAMULIZUMAB IN PREVIOUSLY TREATED, ADVANCED STAGE MYCOSIS FUNGOIDES AND SÉZARY SYNDROME PATIENTS: A POST-HOC ANALYSIS OF THE MAVORIC STUDY

    Nov 1, 2019, 00:00

  • PMU59 ANALYSIS OF THE EVOLUTION IN THE ACCESS TO MEDICINES IN ITALY IN THE LAST 5 YEARS (2014-2018)

    Nov 1, 2019, 00:00

  • PMD2 IMPLANTABLE CARDIAC MONITORS (BIOMONITOR 2-AF, CONFIRM RX INSERTABLE CARDIAC MONITOR AND REVEAL LINQ INSERTABLE CARDIAC MONITORING SYSTEM) TO DETECT ATRIAL FIBRILLATION AFTER CRYPTOGENIC STROKE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PND107 NEUROLOGIST AND PATIENT PREFERENCES IN MULTIPLE SCLEROSIS: UK AND US QUALITATIVE RESEARCH FINDINGS

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PIN61 ANALYSIS ON DIRECT MEDICAL EXPENSES OF PATIENTS WITH PULMONARY TUBERCULOSIS IN CHINA: BASED ON THE CASE OF 17,000 PATIENTS IN WUHAN

    Nov 1, 2019, 00:00

  • Alternative Medicine Information Systems

    Nov 1, 2019, 00:00

  • PCN267 PREVALENCE OF DIFFERENT TYPES OF CANCER IN GERMANY: A COMPARATIVE ANALYSIS OF CLAIMS DATA AND REGISTRY DATA IN GERMANY

    Nov 1, 2019, 00:00

  • PNS210 NATIONAL HEALTH TECHNOLOGY SYSTEM (SINATS) IN PORTUGAL: 4-YEAR LANDMARK ANALYSIS

    Nov 1, 2019, 00:00

  • PMU3 RISK FACTORS FOR ADVERSE DRUG REACTIONS IN PATIENTS UNDERGOING GENERAL SURGERY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PSY47 PATIENT-REPORTED OUTCOMES IN CHINESE ADULT RHEUMATOID ARTHRITIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PSU9 COSTS OF STOMA MANAGEMENT POST COLORECTAL SURGERY IN THE UK HEALTHCARE SYSTEM AND IMPLICATIONS OF POTENTIAL REDUCTION IN NEED FOR OSTOMY PLACEMENT

    Nov 1, 2019, 00:00

  • PCN112 RESEARCH TREND OF THE PHARMACOECONOMIC STUDIES OF SMALL-MOLECULE PROTEIN KINASE INHIBITORS IN CHINA

    Nov 1, 2019, 00:00

  • PMD32 STRUCTURE AND EVOLUTION OF THE FRENCH POSITIVE REIMBURSEMENT LIST FOR MEDICAL DEVICES

    Nov 1, 2019, 00:00

  • PCN431 EFFICACY PREDICTION IN PHASE I ONCOLOGY CLINICAL TRIALS USING DEEP LEARNING

    Nov 1, 2019, 00:00

  • PNS318 NETWORK META-ANALYSES COMBINING RANDOMIZED AND NON-RANDOMIZED EVIDENCE; A NICE HTA REVIEW

    Nov 1, 2019, 00:00

  • PNS339 BAYESIAN NETWORK META-ANALYSES WHERE INFORMATIVE PRIORS WERE USED FOR THE BETWEEN-STUDY HETEROGENEITY; A PRAGMATIC REVIEW

    Nov 1, 2019, 00:00

  • PND31 COST-EFFECTIVENESS ANALYSIS OF 5% LIDOCAINE PLASTER COMPARED TO PREGABALIN IN PATIENTS WITH POSTHERPETIC NEURALGIA IN CHINA

    Nov 1, 2019, 00:00

  • PCN207 COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS OR CHEMOTHERAPY IN GBRCA-MUTATED, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC): A US AND GERMAN HEALTHCARE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDB58 A LITERATRUE REVIEW OF THE ECONOMIC BURDEN OF HYPOGLYCEMIA IN PATIENTS WITH DIABETES MELLITUS IN CHINA

    Nov 1, 2019, 00:00

  • PRO98 ULTRA-ORPHAN MEDICINAL PRODUCTS ASSESSMENT: COMPARISON OF THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND THE INSTITUTE OF CLINICAL AND ECONOMIC REVIEW (ICER) HTA FRAMEWORKS

    Nov 1, 2019, 00:00

  • PNS310 TRENDS IN CLINICAL TRIALS FOR DIGITAL HEALTH TECHNOLOGIES

    Nov 1, 2019, 00:00

  • PNS29 HEALTH RESEARCH AND BIG DATA IN UKRAINE: PERSPECTIVES AND CONCERNS

    Nov 1, 2019, 00:00

  • PIN134 USING TIME-DEPENDENT PROPENSITY SCORE MATCHING TO ACCOUNT FOR PATIENT’S CHANGING CLINICAL STATUS LEADING UP TO THE THERAPEUTIC INTERVENTION: AN EXAMPLE USING REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PNS282 ANALYSIS OF METHODOLOGICAL LIMITATIONS RAISED BY THE FRENCH HEALTH TECHNOLOGY ASSESSMENT ON PUBLISHED EFFICIENCY OPINIONS FROM FEBRUARY 2014 TO MAY 2019

    Nov 1, 2019, 00:00

  • PIH32 EPIDEMIOLOGIC FACTORS PREDISPOSING TO PEDIATRIC OBESITY: A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2019, 00:00

  • PMH26 MODEL DEVELOPMENT FOR ASSESSING COST-EFFECTIVENESS AND PREPARE REIMBURSEMENT DOSSIER OF RTMS IN PATIENT POPULATION WITH TREATMENT-RESISTANT DEPRESSION IN HUNGARY

    Nov 1, 2019, 00:00

  • PRO83 DATA SOURCES USED TO DETERMINE THE TARGET POPULATION SIZE FOR ORPHAN DRUGS - A REVIEW OF GERMAN AMNOG BENEFIT ASSESSMENTS

    Nov 1, 2019, 00:00

  • PIH20 A TARGETED LITERATURE REVIEW OF THE ECONOMIC BURDEN ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME

    Nov 1, 2019, 00:00

  • PMD44 PRICING AND REIMBURSEMENT, AND MARKET ACCESS OF THERAPEUTIC MATERIALS (MEDICAL DEVICES/DIAGNOSTICS/BIOMARKERS) IN SOUTH KOREA.

    Nov 1, 2019, 00:00

  • PCN150 IMPACT OF USING IMMATURE SURVIVAL DATA ON NICE DECISION-MAKING

    Nov 1, 2019, 00:00

  • Drugs Process of Care

    Nov 1, 2019, 00:00

  • PIH12 VARIATIONS IN HEALTH INSURANCE AFFECT HEALTHCARE UTILIZATION IN CHILDREN WITH CROHNS DISEASE IN THE USA

    Nov 1, 2019, 00:00

  • PGI57 NON-BIOLOGIC TREATMENT OF GERMAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASSESSMENT OF HEALTH CARE RESOURCE USE AND COST ASSOCIATED WITH DISEASE ACTIVITY

    Nov 1, 2019, 00:00

  • PDB4 A COST OFFSET ANALYSIS (COA) COMPARING REAL-TIME CONTINUOUS GLUCOSE MONITORING (RT-CGM) WITH INTERMITTENT SCANNING CONTINUOUS GLUCOSE MONITORING (IS-CGM) IN TYPE 1 DIABETES (T1D) SUBJECTS WITH IMPAIRED HYPOGLYCEMIA AWARENESS IN EIGHT C ...

    Nov 1, 2019, 00:00

  • Multiple Diseases - Organizational Practices

    Nov 1, 2019, 00:00

  • PNS220 SUBMISSION PROCESS AND REQUIREMENTS OF NORDIC HEALTH TECHNOLOGY ASSESSMENT (HTA) AUTHORITIES FOR HOSPITAL DRUGS: IMPLICATIONS FOR MARKET ACCESS STRATEGY

    Nov 1, 2019, 00:00

  • PBI91 CHARACTERISTICS AND MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) PATIENTS IN A LARGE REPRESENTATIVE REAL WORLD COHORT

    Nov 1, 2019, 00:00

  • Infectious Diseases - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PDG102 CLINICAL OUTCOMES COMPARING CLOPIDOGREL AND PRASUGREL/ TICAGRELOR IN HONG KONG ACUTE CORONARY SYNDROME POPULATION USING REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PDB22 BUDGET IMPACT ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • CL4 MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF THE EFFICACY AND TOLERABILITY OF APALUTAMIDE AND DAROLUTAMIDE FOR THE TREATMENT OF NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)

    Nov 1, 2019, 00:00

  • PCN375 WHEN EARLY MODELS MAY BE TOO EARLY - PREDICTING SURVIVAL FROM INTERIM ANALYSES

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PMS35 EVIDENCE MAP OF ECONOMIC EVALUATIONS IN RHEUMATOID ARTHRITIS

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Organizational Practices

    Nov 1, 2019, 00:00

  • PNS96 TATTOO PREVALENCE, PERCEPTION AND REGRET IN US ADULTS: A 2017 CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PND32 COST-EFECTIVENESS AND BUDGET IMPACT OF VAGUS NERVE STIMULATION WITH ASPIRE SR MODEL 106 COMPARED TO ANTI-EPILEPTIC DRUGS IN A SUBGROUP OF PATIENTS WITH DRUG RESISTANT EPILEPSY IN PUBLIC SETTING IN TURKEY

    Nov 1, 2019, 00:00

  • PSY23 DIRECT COSTS OF SYSTEMIC LUPUS ERYTHEMATOSUS IN ALBERTA IN REAL WORLD

    Nov 1, 2019, 00:00

  • PNS16 IMPROVING ACCESS TIME IN NUCLEAR CARDIOLOGY TOWARDS QUALITY DELIVERY OF HEALTHCARE SERVICES

    Nov 1, 2019, 00:00

  • PND108 QUALITY OF LIFE OF PATIENTS AFTER ISCHAEMIC STROKE TREATED IN A PROVINCIAL HOSPITAL IN POLAND

    Nov 1, 2019, 00:00

  • PCN450 FITTING A MIXTURE MODEL OF CANCER EXCESS MORTALITY RATES WITH A TRANSFORMATION STEP, TO CANCER RELATIVE SURVIVAL DATA.

    Nov 1, 2019, 00:00

  • PIN85 POTENTIAL PUBLIC HEALTH IMPACT OF REACHING THE WHO/EU TARGET OF 75% INFLUENZA VACCINATION COVERAGE AMONG THE ELDERLY IN GERMANY

    Nov 1, 2019, 00:00

  • PND35 CLINICAL AND ECONOMIC BURDEN OF MIGRAINE IN SPAIN, FRANCE, AND THE UNITED KINGDOM: RESULTS OF A POOLED ANALYSIS

    Nov 1, 2019, 00:00

  • PRO136 PATIENT-REPORTED BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN THE USA AND UK MEASURED USING A DIGITAL APP

    Nov 1, 2019, 00:00

  • PCN272 OBINUTUZUMAB TREATMENT ON 1ST LINE HIGH AND INTERMEDIATE RISK FOLLICULAR LYMPHOMA. SHORT-TERM REDUCTION OF RELAPSED OR REFRACTORY DIRECT MEDICAL COSTS IN ARGENTINA AND CHILE.

    Nov 1, 2019, 00:00

  • PRO41 COST-MINIMIZATION ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE.

    Nov 1, 2019, 00:00

  • PCN282 ASSESSING THE EVOLUTION OF THE PRICING AND ACCESS LANDSCAPE FOR CELL AND GENE THERAPIES IN THE US AND EU3 THROUGH A WEB-BASED PORTAL TO ENGAGE PAYERS

    Nov 1, 2019, 00:00

  • PCN372 METHODOLOGIES FOR ADJUSTMENT OF THE TRIAL OVERALL SURVIVAL FOR TREATMENT SWITCHING: A REVIEW OF NICE SUBMISSIONS

    Nov 1, 2019, 00:00

  • PND126 ANTI-DEMENTIA DRUGS: CHANGING PRESCRIBING PATTERNS WITH THE INTRODUCTION OF GENERIC DRUGS

    Nov 1, 2019, 00:00

  • PCV91 CHANGES IN THE MORTALITY RELATED TO ISCHAEMIC HEART DISEASE IN PEOPLE ABOVE 65 YEARS BETWEEN 1990-2015 IN WHO EUROPEAN REGION

    Nov 1, 2019, 00:00

  • RE4 IS MARKET ACCESS FOR ONCOLOGY TREATMENTS EASIER IN ENGLAND THAN FOR NON-ONCOLOGY TREATMENTS? AN ANALYSIS OF NICE SINGLE TECHNOLOGY APPRAISALS FROM 2017-2019

    Nov 1, 2019, 00:00

  • PDB81 HEALTHCARE RESOURCE USE ASSOCIATED WITH TYPE 2 DIABETES IN AFRICA, EURASIA, THE MIDDLE-EAST AND SOUTH-ASIA: RESULTS FROM THE 7TH WAVE OF THE INTERNATIONAL DIABETES MANAGEMENT PRACTICE STUDY (IDMPS)

    Nov 1, 2019, 00:00

  • PGI13 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN473 PREFERENCES FOR CHEMOTHERAPY SIDE EFFECTS IN SAUDI BREAST CANCER PATIENTS: A DISCRETE-CHOICE EXPERIMENT

    Nov 1, 2019, 00:00

  • PND61 DIRECT AND INDIRECT COSTS OF MIGRAINE IN HEADACHE SPECIALIST CENTERS IN PORTUGAL

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS124 FRAMEWORK CONCEPTS FOR FINANCIAL RISK SHARING IN NOVEL POTENTIALLY CURATIVE MODALITIES

    Nov 1, 2019, 00:00

  • PDG81 EARLY HEALTH TECHNOLOGY ASSESSMENT (HTA): LESSONS LEARNED FROM A RUSSIAN BIOTECHNOLOGY COMPANY

    Nov 1, 2019, 00:00

  • PNS329 ESTIMATION OF A DUTCH TARIFF FOR THE ADULT SOCIAL CARE OUTCOMES TOOLKIT FOUR-LEVEL SELF-COMPLETION TOOL (ASCOT-SCT4)

    Nov 1, 2019, 00:00

  • Neurological Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PSY35 A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENTS EVALUATING RECENTLY APPROVED BIOLOGICAL THERAPIES FOR ADULT PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS IN THE US, CANADA AND UK

    Nov 1, 2019, 00:00

  • PDB119 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN

    Nov 1, 2019, 00:00

  • PNS52 ASSESSMENT OF THE IMPACT OF THE LEVEL OF ASMR ON THE DRUG'S PRICE AND ITS NEGOTIATION TIME WITH THE HEALTH AUTHORITIES IN TREATMENTS THAT BENEFITED FROM THE FRENCH EARLY ACCESS PROGRAM

    Nov 1, 2019, 00:00

  • PCN505 COSTS AND TREATMENT PATHWAYS OF OVARIAN CANCER CARE IN KAZAKHSTAN: RETROSPECTIVE ANALYSIS OF PATIENT-LEVEL ELECTRONIC HEALTH RECORDS

    Nov 1, 2019, 00:00

  • NO Specific Disease - Organizational Practices

    Nov 1, 2019, 00:00

  • TP3 CHARACTERIZING AND COMPARING US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY RECEIPT OF MEDICATION-ASSISTED TREATMENT (MAT)

    Nov 1, 2019, 00:00

  • PCN377 WHERE DO WE GO WITH WHOLE GENOME SEQUENCING IN ONCOLOGY? USING SCENARIO DRAFTING TO EXPLORE FUTURE DEVELOPMENTS

    Nov 1, 2019, 00:00

  • PNS265 MULTI-CRITERIA DECISION ANALYSIS AS A SUPPORTIVE TOOL FOR EFFICIENCY MEASURING IN HEALTH CARE

    Nov 1, 2019, 00:00

  • PND87 SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUES (HSUVS) IN MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • PRS39 THE ECONOMIC BURDEN OF ASTHMA

    Nov 1, 2019, 00:00

  • PMD11 MEASURING THE ECONOMIC IMPACT OF THERAPEUTIC PLASMA EXCHANGE: A SINGLE INSTITUTION STUDY IN XIAMEN, CHINA

    Nov 1, 2019, 00:00

  • PMS22 ANNUAL COST OF PATIENTS UNDERGOING A TOTAL KNEE REPLACEMENT IN FRANCE

    Nov 1, 2019, 00:00

  • PDB91 AN MCDA APPROACH IN THE EVALUATION OF NEW TECHNOLOGIES FOR FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT

    Nov 1, 2019, 00:00

  • PND114 REAL WORLD PATIENT SURVEY ON HOW MIGRAINE AFFECTS EGYPTIAN SOCIAL AND WORK LIFE

    Nov 1, 2019, 00:00

  • PCN490 MAKING OUTCOME-BASED PAYMENT A REALITY IN THE NATIONAL HEALTH SERVICE FOR ENGLAND

    Nov 1, 2019, 00:00

  • PCN382 TRASTUZUMAB IN THE TREATMENT OF HER2-POSITIVE EARLY ANDLOCALLY ADVANCED BREAST CANCER: THE FIRST HTA REPORT OF INEAS-TUNISIA

    Nov 1, 2019, 00:00

  • NO Specific Disease - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN345 A REVIEW OF DIFFERENCES IN DECISION-MAKING ACROSS NICE HEALTH TECHNOLOGY ASSESSMENTS OF NIVOLUMAB

    Nov 1, 2019, 00:00

  • PIN101 ECONOMIC IMPACT OF ICU-ACQUIRED MULTI-DRUG RESISTANT BACTERIAL INFECTIONS: EVIDENCE FROM SOUTHERN EUROPE

    Nov 1, 2019, 00:00

  • PNS355 HOW INVOLVED SHOULD PAYERS BE IN THE DEVELOPMENTS OF TARGET PRODUCT PROFILE (TPP), PRODUCT DEVELOPMENT PLAN (PDP) AND DESIGN OF CLINICAL TRIALS (DOCT)

    Nov 1, 2019, 00:00

  • PCN456 REAL WORLD HEALTH RELATED QUALITY OF LIFE (HRQOL) FOR FIRST LINE RECURRENT/ METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) PATIENTS

    Nov 1, 2019, 00:00

  • PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS

    Nov 1, 2019, 00:00

  • PNS78 RECONCILING ACEA AND MCDA: IS THERE A WAY FORWARD FOR MEASURING COST-EFFECTIVENESS IN THE U.S. HEALTHCARE SETTING?

    Nov 1, 2019, 00:00

  • PCN288 HOW IS METASTATIC MELANOMA TREATED IN THE PUBLIC HEALTH SYSTEM IN BRAZIL?: A CALL FOR CHANGE

    Nov 1, 2019, 00:00

  • PMU107 INSIGHTS INTO REIMBURSEMENT RATES AND TIMELINES FOR ORPHAN DRUGS IN IRELAND

    Nov 1, 2019, 00:00

  • PCV53 COST-EFFECTIVENESS OF THE CNIC POLYPILL - FIXED DOSE COMBINATION OF ACETYLSALICYLIC ACID, RAMIPRIL AND ATORVASTATIN - FOR THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN GREECE

    Nov 1, 2019, 00:00

  • PDG38 RELATIONSHIP BETWEEN RELIGIOSITY-SPIRITUALITY AND MEDICATION ADHERENCE AMONG PATIENTS WITH CARDIOVASCULAR DISEASES: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PDB59 EVALUATING THE COST-UTILITY OF ADDING SODIUM-GLUCOSE COTRANSPORTER INHIBITORS TO A BASAL-BOLUS INSULIN REGIMEN IN PATIENTS WITH TYPE 1 DIABETES IN THE UK: AN ANALYSIS USING THE PRIME DIABETES MODEL

    Nov 1, 2019, 00:00

  • PRO25 COST OF HEALTHCARE RESOURCE UTILIZATION IN INTERSTITIAL LUNG DISEASES IN GERMANY IN 2017

    Nov 1, 2019, 00:00

  • PCN374 BETTER LATE THAN NEVER: THE DYNAMICS OF NICE DECISION-MAKING UNDER THE NEW MODEL OF THE CDF

    Nov 1, 2019, 00:00

  • PCN25 IMPACT OF GEMTUZUMAB OZOGAMICIN ON THE IRISH HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PNS306 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF RANDOMIZED CONTROLLED TRIALS

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • Stated Preference Patient Satisfaction Research

    Nov 1, 2019, 00:00

  • PNS269 PERSPECTIVES ON PRICING AND REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE GREEK HEALTHCARE SETTING: A QUALITATIVE STUDY

    Nov 1, 2019, 00:00

  • PCN484 SYSTEMATIC REVIEW OF A DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME MEASURE IN PATIENTS WITH MULTIPLE MYELOMA: EORTC QLQ-MY20 INSTRUMENT DEVELOPMENT AND VALIDATION

    Nov 1, 2019, 00:00

  • ON7 TIME-TO-TREATMENT DISCONTINUATION (TTD) AS A PRAGMATIC PREDICTOR OF OVERALL SURVIVAL (OS) IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) - REAL-WORLD PERSPECTIVE

    Nov 1, 2019, 00:00

  • PBI74 MARKET ACCESS LANDSCAPE FOR BIOSIMILARS IN SWEDEN: AN UNTAPPED POTENTIAL?

    Nov 1, 2019, 00:00

  • PNS158 HEALTH ECONOMIC VALUE OF BLOOD IN SUB-SAHARAN AFRICA: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PND63 ASSOCIATION BETWEEN TYPE OF SURGERY AND DEVELOPMENT OF PARKINSON'S DISEASE: A NESTED CASE-CONTROL STUDY USING A US INSURANCE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PMU118 USE OF COMPUTER-ASSISTED METHODS TO REALIZE THE CONCEPT OF A LIVING SYSTEMATIC REVIEW VIA AN ONLINE PLATFORM

    Nov 1, 2019, 00:00

  • PDB2 USING REAL WORLD DATA TO EXAMINE TRIGLYCERIDES, LDL-CHOLESTEROL, AND HDL-CHOLESTEROL AS PREDICTORS OF PROGRESSION FROM NONALCOHOLIC STEATOHEPATITIS TO HEPATOCELLULAR CANCER AND LIVER CIRRHOSIS

    Nov 1, 2019, 00:00

  • Mental Health - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PMD42 THE DIRECT COSTS ASSOCIATED WITH POSTERIOR CAPSULE OPACIFICATION IN THE NETHERLANDS: A PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS394 DEVELOPMENT OF A MULTIPLICATIVE MULTI-ATTRIBUTE AND SINGLE-ATTRIBUTE UTILITY FUNCTION FOR THE HUI3 IN JAPAN

    Nov 1, 2019, 00:00

  • PND81 LANDSCAPE ASSESSMENT AND KEY HTA CONSIDERATIONS IN ALZHEIMER'S DISEASE

    Nov 1, 2019, 00:00

  • PCN5 REAL-WORLD DATA OF NIVOLUMAB IN NON-SMALL-CELL LUNG CANCER PATIENTS IN GREECE

    Nov 1, 2019, 00:00

  • PDG52 CONSISTENCY OF NEW DRUG PRICING IN KOREA: BRIDGING VARIATIONS AMONG PERSONNEL IN PRICE NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PRS30 PRAGMATIC META-ANALYSIS OF PROPORTIONAL ASSIST VENTILATION+ VERSUS PRESSURE SUPPORT VENTILATION AND ITS IMPACT ON COST EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PCN279 EFFECT OF THE CHANGE IN COST-EFFECTIVENESS THRESHOLD ON THE NEWLY LISTED ANTICANCER DRUG PRICES IN THE NATIONAL HEALTH INSURANCE OF SOUTH KOREA

    Nov 1, 2019, 00:00
  • «
  • 51
  • 52
  • 53
  • 54 (current)
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • »